What is Leerink Partnrs’ Estimate for GPCR FY2025 Earnings?

Structure Therapeutics Inc. (NASDAQ:GPCR) – Investment analysts at Leerink Partnrs decreased their FY2025 earnings per share estimates for Structure Therapeutics in a report issued on Tuesday, December 3rd. Leerink Partnrs analyst D. Risinger now forecasts that the company will earn $1.94 per share for the year, down from their previous estimate of $2.04. The consensus estimate for Structure Therapeutics’ current full-year earnings is ($0.80) per share.

GPCR has been the topic of several other research reports. Cantor Fitzgerald restated an “overweight” rating and set a $65.00 target price on shares of Structure Therapeutics in a report on Monday, September 23rd. Morgan Stanley assumed coverage on Structure Therapeutics in a report on Monday, September 23rd. They set an “overweight” rating and a $118.00 target price on the stock. JMP Securities decreased their target price on Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating on the stock in a report on Friday, August 9th. Finally, HC Wainwright began coverage on Structure Therapeutics in a research note on Wednesday. They set a “buy” rating and a $80.00 price target on the stock. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $85.67.

Structure Therapeutics Stock Performance

Shares of GPCR stock opened at $33.55 on Thursday. The stock’s fifty day moving average is $37.66 and its 200-day moving average is $39.38. Structure Therapeutics has a 52 week low of $26.61 and a 52 week high of $64.45.

Hedge Funds Weigh In On Structure Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Sandia Investment Management LP acquired a new position in Structure Therapeutics in the second quarter valued at about $39,000. Assetmark Inc. raised its position in shares of Structure Therapeutics by 120.0% during the third quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock worth $58,000 after purchasing an additional 719 shares during the period. Quarry LP acquired a new stake in shares of Structure Therapeutics during the second quarter worth about $79,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Structure Therapeutics by 60.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock worth $158,000 after purchasing an additional 1,420 shares during the period. Finally, Dearborn Partners LLC acquired a new stake in shares of Structure Therapeutics during the third quarter worth about $202,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.